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Abstract
Background—The FDA currently recommends at least 4 hours of recipient monitoring to detect
early infusion reactions; recent catastrophic reactions to “first in man” biological agents have
emphasized the importance of this rule for initial studies of new products. The value of such
monitoring for better established agents is less obvious.
Methods—We therefore reviewed infusion-related adverse events (AEs) following administration
of ex-vivo expanded T cell products (antigen specific CTLs, allodepleted T cells and genetically
modified T cells) on Investigational New Drug (IND) studies in our center.
Results—From 1998 to 2008, we infused 381 T cell products to 180 recipients, enrolled on 18
studies, receiving T cells targeting malignancies or post-transplant viral infections. There were no
Grade 3-4 infusion reactions during initial monitoring or 24 hour follow-up. Twenty four mild (grade
1-2) adverse events (AEs) occurred in 21 infusions either during or immediately following infusion
(up to 6 hours), most commonly nausea and vomiting (10/24; 41.6%), likely due to the DMSO
cryoprotectant, and hypotension (20.8%), attributable to diphenhydramine pre-medication. 22
additional non-severe events were reported within 24 hours of infusion, most commonly culture
negative fever, chills and nausea. Increased risk of adverse effects was associated with age (IRR
0.98; 95% CI 0.96-1.00; p=0.05), while an increase risk of immediate infusion-related events was
higher in patients reporting allergies (IRR 2.72; 95% CI 1.00-7.40; p=0.05); sex, disease type or T
cell source (allogeneic or autologous) had no effect on frequency of adverse events.
Discussion—Hence infusion of T cells is safe in the outpatient setting and associated with no
severe reactions, so that monitoring for one hour after infusion is likely sufficient. As many of the
AEs were attributable to diphenhydramine premedication, a lower dose (0.25mg/kg) should be
selected.
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INTRODUCTION
T cell therapies can benefit a range of disorders including cancer, viral infections, invasive
fungal disease, and autoimmune and allergic disorders(1-9). The number of trials exploring
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this approach has increased substantially over the past decade and the clinical trials database
currently lists 180 approved T cell immunotherapy protocols in 30 countries around the world
(10). While clinical toxicities and adverse event profiles have been reported for other cell-based
infusion products (11;12), there has been no comprehensive evaluation of infusion reactions
after administration of ex-vivo manipulated T cells. Infusion of T cells could mediate a panoply
of unintended effects, including fever and nonspecific constitutional symptoms, as a
consequence of inflammatory mediator release or cytokine secretion, by transmission of
infectious agents or following acute lung injury due to their entrapment in the pulmonary
vasculature (13).
The FDA currently recommends at least 4 hours of recipient monitoring following
administration of ex-vivo expanded T cells and two recent severe adverse events (AEs) after
“first in man” biological agents have emphasized the importance of this rule for initial clinical
studies using new products. In the first case, a patient received T cells modified to express a
chimeric antigen receptor (CAR) specific to the B cell tumor antigen CD19 that also contained
a co-stimulatory moiety (CD28). The patient was lymphodepleted with cyclophosphamide
prior to the infusion. Within 48 hours the patient developed fever, hypotension, dyspnea, and
renal failure, with negative blood cultures, and progressed to a fatal outcome (14). A second
patient received T cells transduced with a chimeric antigen receptor targeting HER2/neu
containing both the CD28 and 4-1BB costimulatory domains(15). Within 4 hours of infusion,
this patient developed rapidly progressive respiratory distress requiring ventilation(15) and
subsequently died. Although these events were rare, they emphasize why a high level of
monitoring is required for any first in man study; however the relevance for more established
T cell infusion products is not known. We therefore retrospectively studied the incidence and
severity of immediate and early adverse events occurring in subjects enrolled on 18 different
IND studies of ex vivo manipulated T cell cells over a 10 year period at our institution.
METHODS
Patient Details
We reviewed the charts, infusion records, and adverse event reports of 180 patients who
received 381 infusions of ex-vivo expanded T cells on IND studies at the Center for Cell and
Gene Therapy at Baylor College of Medicine, The Methodist Hospital and Texas Children’s
Hospital in Houston, Texas from January 1, 1998 to November 20, 2008. Included in this study
were patients who received antigen-specific cytotoxic T cells, allodepleted T cells, or
genetically modified T cells, on 18 FDA-approved investigational new drug studies. The
infused T cells targeted malignancies or viral infections after hemopoietic stem cell transplant
(HSCT). Cell doses were protocol specific and ranged from 104/kg up to 2 × 108/m2. Patients
were premedicated with intravenous diphenhydramine (0.5-1mg/kg, with a maximum dose of
50mg) and Tylenol (10mg/kg up to a maximum dose of 625mg) prior to infusion. All cellular
products were cryopreserved using 10% DMSO and administered intravenously over 1-15
minutes immediately after thawing. The types of cellular products are summarized in Table 1.
All patients were treated on IRB approved protocols conducted under INDs after approval by
the FDA. If T cells were genetically modified or if they were stimulated by antigen presenting
cells that were genetically modified the studies were also reviewed by the Recombinant DNA
Advisory Committee of the National Institutes of Health and the Institutional Biosafety
Committee. This collated analysis, combining data on infusion safety from all 18 studies was
also approved by the IRB at Baylor College of Medicine. Adverse events were collected and
graded on case report forms using NCI common toxicity criteria (version 2 or 3 depending on
when the study was initiated).
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Outcome data from some of these studies have been reported (16-26) but a detailed analysis
of infusion-related adverse events has not been previously presented.
Statistical methods
We initially used descriptive statistics (mean, standard deviation, median and range) to analyze
the data. All patients who received T-cell infusions were included in the analysis. Adverse
event data were summarized in the form of tables. Incidence tables were generated to
summarize incidence of patients reporting at least one episode of each specific adverse event
and incidence of serious adverse events. The total number of episodes for each event reported,
the grade and attribution to study therapy of each episode reported were summarized. The
incidence of adverse events was also listed by age group, presence of an allergy and source of
T cells, and compared by Fisher’s exact test. The association of the incidence of AE with the
type of cells, gender, age at infusion and presence of allergy was then further analyzed by the
Poisson regression model using the generalized estimation equation (GEE) to account for the
correlation of AE within subjects, and we report estimates of the association and the robust
95% confidence intervals. All p-values are 2-sided, with P < 0.05 considered statistically
significant. All statistical analyses used R and STATA 9.0 software packages.
RESULTS
Patient Characteristics
A total of 381 T cell products were given to 180 patients (some studies infused more than two
products (23) or had more than one infusion) during the ten year period between 1998 to 2008.
Patient characteristics are summarized in Table 2. The types of T cell products infused are
summarized in Table 3.
Adverse Events Resulting from the Infusion are Non-Severe
Twenty four grade 1-2 adverse events (AEs) occurred in 21 infusions of 22 ex vivo expanded
T cell products (one patient was enrolled on a study where two products were administered),
giving an incidence of 6.55%, either during infusion or the immediate post-infusion monitoring
period (which lasted between 1 – 6 hours). Figure 1 summarizes the observed events. Figure
2 enumerates an additional 22 events (incidence of reported or observed adverse events
occurring in the 24 hour window following T cell infusion). Again, no severe adverse events
that were related to the T cell products were noted. Overall, we observed a total of 46 immediate
(within 24 hours) non-severe adverse events (12.56%) and no severe adverse events following
the infusion of ex vivo manipulated T cells. The most common adverse events were nausea/
vomiting and hypotension.
The Majority of Adverse Events are Related to DMSO or Diphenhydramine
All infusions consisted of T cell products suspended in media containing 10% DMSO as a
cryoprotectant and the cells were not washed prior to infusions. Subjects received the infusions
after premedication with diphenhydramine and acetaminophen, except when contraindicated
by the presence of allergies or by concomitant medications that would produce unwanted
interactions. As seen in Figure 3, most of the immediate adverse events noted were attributed
to DMSO (e.g. nausea/vomiting, taste disturbance) or diphenhydramine (e.g. hypotension,
transient hypoxia resulting from sedation).
Relationship of Adverse Events to Other factors
For analysis, adverse events (AEs) were defined as an event grade 1 or higher, possibly,
probably, or definitely related to the T cell infusion. Because all adverse events were non-
severe, no attempt was made to distinguish AE grades in the analysis.
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Adverse events were first summarized by infusion episode. Fisher’s exact analysis of all T cell
product infusions grouped by patient age, patient ethnicity, or cell source did not reveal any
associations with increased risks for adverse events. The very young and the very old were no
more susceptible to untoward side effects from T cell infusions (Table 4a). Neither the patient’s
ethnicity (Table 4b) nor increasing antigenic mismatch between donor and recipient cells
(Table 4c & 4d) contributed to a higher incidence of AEs. T cells from both allogeneic and
autologous sources resulted in similar rates of adverse events following infusions (Table 4c),
and allogeneic cells that were mismatched at more than 2 antigens are no more associated with
adverse events than donor T cells matched at 5/6 and 6/6 HLA loci. (Table 4d).
Analysis by infusion episodes, however, is not very comprehensive, as AE within a subject are
not statistically independent. We thus performed more rigorous data analysis of the data by
individual subject. Since the number of AE events from each individual should follow a Poisson
distribution, we used a Poisson regression model with a generalized estimating equation (GEE)
for correlated count data. We estimated the incidence rate (IR) per subject, and by covariates
and in this multivariate Poisson regression model we compared: autologous vs allogeneic stem
cell source of T cells, patient gender, age at infusion, and the presence of allergies. We also
fitted the Poisson regression model to the level of antigen mismatch for recipients of allogeneic
T cells. Stratifying adverse event data by incidence rates per patient results in significantly
lower incidences seen as patient age increases. Immediate adverse event rates are also increased
in patients with documented allergies. (IRR = incidence rate ratio, AE = adverse event) In our
analysis of patients with allergies, we classified patients whose allergy status is undocumented
within the allergy group, to make for a more conservative estimate of the effects of allergies
and to avoid dropping any patients from our calculations. By this approach we found a
significant effect of older age on the probability of both immediate and total adverse events.
The presence of allergies also predisposed patients to develop immediate infusion reactions.
(Table 5).
DISCUSSION
Most complex biological products such as ex-vivo expanded T cells are prepared following
multi-step procedures – including cell activation, ex vivo expansion using complex media,
serum and cytokines, and genetic modification, all of which may increase the risk for
subsequent infusion reactions from infection, contamination or hypersensitivity (27). Several
studies have previously looked at the safety profile of unmanipulated or minimally manipulated
cellular therapies (11;12), but our study was aimed at evaluating the consequences of infusing
ex-vivo expanded T cells. Our intent was to provide guidance for immediate safety monitoring
after administration of these cellular products. We identified an overall adverse event (AE)
incidence rate of 17.3%, and none of these AE’s were severe. This excellent safety record is
similar to preliminary experience with other cell-based therapies (28) Of note, the majority of
AEs in our analysis could be attributed to either the cryoprotectant (DMSO) or the
diphenhydramine used as premedication rather than to the T cells themselves.
Of the adverse events observed, only mild immune/inflammatory responses (constitutional
symptoms, mild fever, chills) reported on 10 occasions within 24 hours of T cell infusion are
likely mediated by the ex vivo generated T cell products; a similar rate of such symptoms have
been reported in studies of other cell products (29). Since we found an increased risk of infusion
reactions in recipients with documented allergies, we recommend careful monitoring of those
patients who report such predispositions. We observed no differences in adverse event rates if
patients are grouped according to cell source used for infusion.
DMSO is a commonly used cryoprotectant, and a variety of methods have been proposed to
minimize the adverse effects of this agent. Washing cells prior to infusion is effective, but
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introduces additional variables into analysis of product functionality that we believed
unjustified by the low rate and severity of infusion reactions. Fractionated cell infusions (30)
and the use of strawberry flavored lollipops (31) have been shown to decrease the incidence
of DMSO-related clinical effects.
The patients in this series received relatively low infusion volumes (0.7mL to 58 mL) and T
cell numbers (3 × 105/kg to 2 × 108 cells/m2). While larger quantities, or first in man products
may have an entirely different safety profile due, for example, to pulmonary vascular
congestion or cytokine storms (14), our experience with these more established, smaller scale
infusions, clearly shows immediate safety.
Hence, we propose that one hour monitoring post-infusion, with clear instructions to the
patients to report any adverse events they see before the next clinic visit, should be sufficient
to maintain this excellent safety record. Indeed, reduction of the dosage of diphenhydramine
may reduce adverse events, such as mild hypotension, still further.
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Figure 1. Adverse Events During T Cell Infusion/Post-Infusion Monitoring
Twenty four adverse reactions during infusion or the immediate post-infusion monitoring
period amount to an incidence of 6.5% adverse events in 366 infusions of 381 T cell products.
Two grade 3 reactions, 2 grade 2 reactions, and 2 grade 1 reactions were also reported but were
considered unrelated to the T cell products. All adverse events that were possibly/definitely
related to the T cell infusion were non severe (grade 1-2). Adding the adverse events related
to T cell infusion reported within 24 hours results in an incidence of 12.5%.
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Figure 2. Adverse Events Reported Within 24 Hours
An additional 266 adverse events were reported within a day after infusion. A total of twenty
two events possibly or definitely related to the ex vivo manipulated T cell product are listed
here (all of which are non-severe/grade 1-2). Both the frequency of each adverse event and the
severity of the reaction are noted.
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Figure 3. Adverse Events Attributable to DMSO or Diphenhydramine
Most of the (a) immediate adverse events seen during infusion and the post-infusion period are
attributable to either DMSO or diphenhydramine. There were an additional five adverse events
attributable to DMSO seen or reported (b) within 24 hours of infusion, with most events at this
time period conceivably resulting from a mild inflammatory process mediated by the T cell
products. None of the adverse events were severe enough to be a cause of concern.
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Table 1
Summary of Studies
Study Name T Cell Product Dose Range (cells/m2) Indication
ANGEL NCT00058617 Autologous EBV-specific CTL 2 × 107 – 2 × 108 Relapsed EBV-positive
Hodgkin’s disease lymphoma
(17)
ANGELA NCT00058773 Autologous EBV-specific CTL 2 × 107 – 2 × 108 EBV-positive Hodgkin’s
disease post autograft (17)
SCAEBV NCT00608608 Autologous EBV-specific CTL 1 × 107 – 1 × 108 Severe chronic active EBV
infection (16)
EUCLID NCT00058604 Autologous EBV-specific CTL 2 × 107 – 1 × 108 Prevention and treatment of
EBV lymphoma following solid
organ transplantation (21)
NPC Autologous EBV-specific CTL 2 × 107 – 2 × 108 Nasopharyngeal carcinoma (18)
CLANC NCT00608257 Autologous EBV-specific CTL 2 × 107 – 1 × 108 EBV-positive nasopharyngeal
cancer after lymphodepletion
(24)
NATELLA NCT00682864 Autologous LMP1/LMP2 specific CTL 2 × 107 – 2 × 108 Nasopharyngeal carcinoma
NESTLES NCT00085930 Autologous 14g2a-zeta-CAR-transduced CTL and
14g2a-zeta-CAR-transduced EBV-specific CTL
2 × 107 High-risk Neuroblastoma (23)




ALCI NCT00671164 Autologous or donor-derived LMP1/LMP2 specific
CTL
2 × 107 – 1 × 108 EBV-positive lymphoma,
lymphoepithelioma, or severe
chronic EBV




ETNA NCT00058604 Donor-derived EBV-specific CTL 2 × 107 – 1.2 × 108 Immune reconstitution in
allogeneic/mismatch HSCT
recipients (26)
LYPTAIST NCT00111033 Donor-derived adenovirus/EBV-specific CTL 5 × 106 – 1.35 × 108 Adenovirus and EBV infection
post allogeneic HSCT (25)
VICTA NCT00078533 Donor-derived CMV/adenovirus/EBV-specific CTL 1 × 107 – 1 × 108 Prophylaxis of CMV,
adenovirus and EBV infection
post allogeneic HSCT (20)
CHALLAH NCT00711035 Third party allogeneic adenovirus/EBV/CMV-
specific CTL




RFT-DGA NCT00622297 Donor-derived allodepleted T cells 1 × 104 – 5 × 106* Immune reconstitution post-
haploidentical stem cell
transplant (19)
RAFAHS NCT00586274 Donor-derived allodepleted T cells 1 × 104* Immune reconstitution post-
haploidentical stem cell
transplant for Fanconi anemia
(19)
HIMRFT NCT00586547 Allodepleted T cells 1 × 103 – 1 × 104 * Immune reconstitution post-
reduced intensity haploidentical
stem cell transplant (19)
*
cell doses are expressed per kg
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Table 2
Patient Characteristics
Characteristic T cell Recipients

















Post-solid organ transplant 11











Acute Biphenotypic Leukemia 1













Cruz et al. Page 13
Table 3
Types of Infusion










CAR-transduced EBV-specific CTLs 15
CAR-transduced OKT3 blasts 15
LMP2a-specific CTLs 44
LMP1/LMP2a-specific CTLs 52
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Table 4
Incidence of Adverse Events Analyzed by T Cell Infusion
a. Adverse events subgrouped by age











b. Adverse events subgrouped by presence of allergies











c. Adverse events subgrouped by T cell source











d. Adverse events in allogeneic T cell products subgrouped by extent of antigenic mismatch
No. of AE 4/6 5/6 6/6 Unspecified
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0 50 6 39 11
94.34 85.71 88.64 91.67
1 1 1 4 1
1.89 14.29 9.09 8.33
2 2 0 1 0
3.77 0 2.27 0
Total 53 7 44 12
Fisher’s Exact 0.458
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Table 5
Incidence of Adverse Events Analyzed Per Patient
IRR 95% Confidence Interval p-value
Immediate AE
Auto vs Allo 0.27 0.07 – 1.11 0.07
Male vs Female 0.59 0.23 – 1.52 0.28
Age at Infusion 0.97 0.94 – 1.00 0.05
Allergy vs No Allergy 2.72 1.00-7.40 0.05
AEs After 24 Hours
Auto vs Allo 1.32 0.34 - 5.05 0.69
Male vs Female 0.49 0.19 - 1.27 0.14
Age at Infusion 0.99 0.96 - 1.01 0.27
Allergy vs No Allergy 0.77 0.31 – 1.87 0.56
Total AEs
Auto vs Allo 0.58 0.22 – 1.54 0.28
Male vs Female 0.56 0.29 – 1.11 0.1
Age at Infusion 0.98 0.96 – 1.00 0.05
Allergy vs No Allergy 1.41 0.73 – 2.71 0.31
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